INTRODUCTION AND OBJECTIVES: African American (AA) men tend to present with higher risk prostate cancer (CaP) with poorer prognosis than a non-AA cohort. It has been postulated that the burden of anterior prostate lesions (APL) may be greater and more aggressive in AA men leading to CaP evasion of detection and increased mortality. We aim to compare the rates and grade of APLs in AA and non-AA males.
METHODS: A retrospective database was established including 463 men (64 AA, 399 non-AA) at an academic hospital who underwent prostate biopsy following MRI from to June 2014 to September 2016. These patients did not carry a diagnosis of CaP. Multiparametric magnetic resonance imaging (mpMRI) was used to identify lesions suspicious for CaP. A 3-Tesla MRI machine and Invivo software was utilized for fusion.
RESULTS: The AA male population studied showed no significant difference in age (p¼0.92), or gland volume (p¼0.73). However, median prostate specific antigen (PSA) (7.9 vs. 6.3; p<0.001) and PSA density (PSAD) (.134 vs.111; p<0.03) were significantly higher in the AA population. Despite this, there were fewer AA men with anterior lesions (15/64, 23.4%) then non-AA men (112/399, 28.1%). Additionally, there was no significant difference in maximum lesion size from the AA group to the control. When these lesions were biopsied, the ratios of both APLs and total lesions shown to be Gleason 7 or higher were equivalent for both populations.
CONCLUSIONS: AA men were slightly less likely to have an anterior lesion mpMRI, but had equivalent total lesions and maximal lesion dimensions. Despite higher PSAD, AA men were equally likely to have clinically significant APLs and CaP in general. These findings contradict conventional hypotheses in urology and may implicate a more complex multifactorial cause for the prognostic disparity observed. CONCLUSIONS: African American ethnicity was associated with a 31% increased risk of biochemical recurrence when adjusted comparisons were performed. Further research is needed to determine if these observed differences in the rate of BCR are modifiable among AA men with high risk disease.
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MP14-18 ALKALINE PHOSPHATASE VELOCITY PREDICTS METASTASIS AMONG PROSTATE CANCER PATIENTS WHO EXPERIENCE BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
Carolyn Salter*, Bethesda, MD; Jennifer Cullen, Rockville, MD; Inger Rosner, Bethesda, MD; Huai-Ching (Claire) Kuo, Rockville, MD; Adam Metwalli, Bethesda, MD INTRODUCTION AND OBJECTIVES: Most patients undergoing radical prostatectomy (RP) for treatment of prostate cancer (CaP) will not develop biochemical recurrence (BCR) or distant metastasis (dMET). Risk factors have been difficult to establish and the role of neoadjuvant, adjuvant, and/or salvage therapy in preventing or delaying these events is not well understood. This study builds on previous work examining alkaline phosphatase velocity (APV) in predicting dMET for castrate-resistant CaP (CRPC) patients, in a large, racially diverse cohort of patients treated in an equal access military health care system.
METHODS: This retrospective cohort study examined CaP patients enrolled in the Center for Prostate Disease Research (CPDR) multi-center national database who underwent RP and subsequently experienced BCR (n¼1725). BCR was defined as a PSA 0.2 ng/mL at 8 weeks post-RP, followed by a confirmatory PSA 0.2 ng/mL. APV was computed as the slope of the linear regression line of all alkaline phosphatase (AP) values after RP and prior to dMETs. APV values in the uppermost quartile were defined as 00 rapid 00 and compared to those in the lower 3 quartiles combined. Salvage therapies were categorized as: hormone therapy only, external radiation therapy only, or multi-treatment. Unadjusted Kaplan Meier curves and multivariable Cox Proportional Hazards analysis were used to model time to dMET. e168 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
